Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), will examine the safety of its novel investigational recombinant antibody MYO-029 in a phase one/two clinical trial in adult patients with muscular dystrophy (MD)... click link for more info.

Continue to Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029 on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz